Summary
Definición
Anamnesis y examen
Principales factores de diagnóstico
- family history of childhood seizures
- staring episode, lasting 5 to 10 seconds; several times per day with no aura/postictal state
- childhood onset
- normal physical exam
- hyperventilation-induced seizure
Otros factores de diagnóstico
- simple automatisms
- recent decline in school performance
- complex automatisms
- early onset (before age 4 years)
Factores de riesgo
- family/genetic history of childhood absence epilepsy or juvenile myoclonic epilepsy
- acquired brain injury: for example, hypoxia-ischemia, trauma, infection
- other congenital inborn errors of metabolism, structural defects, chromosomal abnormalities
- developmental delay or intellectual disability
- female sex
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- EEG
Pruebas diagnósticas que deben considerarse
- MRI brain
- testing for metabolic disorders (e.g., serum amino acids, urine organic acids, lactate pyruvate or specific enzymatic tests)
- cerebrospinal fluid and serum glucose
Pruebas emergentes
- gene testing
Algoritmo de tratamiento
typical absence seizures without a history of generalized tonic-clonic seizures (childhood absence epilepsy)
typical absence seizures with a history of generalized tonic-clonic seizures (CAE, JAE, JME)
atypical absence seizures
refractory to treatment
Colaboradores
Autores
Judith L. Z. Weisenberg, MD
Assistant Professor of Neurology
Washington University Medical School
St. Louis
MO
Divulgaciones
JLZW states that she has no competing interests.
Agradecimientos
Dr Judith L. Z. Weisenberg would like to gratefully acknowledge Dr Michael Wong, a previous contributor to this topic.
Divulgaciones
MW declares that he has no competing interests.
Revisores por pares
Anita Devlin, MBBS, MD
Consultant Paediatric Neurologist
Royal Victoria Infirmary
NHS Foundation Trust
Newcastle-upon-Tyne
UK
Divulgaciones
AD and two epilepsy nurses from her department have been reimbursed by UCB Pharma, the manufacturer of levetiracetum, for attending several conferences. One of the epilepsy nurses received a one-off sponsorship payment from UCB Pharma to cover the initial set-up costs of the adolescent epilepsy support group. One epilepsy nurse has been reimbursed by Cyberonics, the manufacturer of vagal nerve stimulators, for attending one or more conferences.
Cigdem Akman, MD
Division of Pediatric Neurology
Columbia University College of Physicians and Surgeons
New York
NY
Divulgaciones
CA declares that he has no competing interests.
Angus A. Wilfong, MD
Associate Professor
Pediatrics and Neurology
Baylor College of Medicine
Medical Director
Comprehensive Epilepsy Program
Texas Children's Hospital
Houston
TX
Divulgaciones
AAW declares that he has no competing interests.
Helen Cross, MB, ChB, PhD, FRCP, FRCPCH
Head of Neurosciences Unit
The Prince of Wales’s Chair of Childhood Epilepsy
National Centre for Young People with Epilepsy
London
UK
Divulgaciones
HC has received research funds from HAS, Epilepsy Research UK, SHS, and the Milk Development Council. She has received funding for an epilepsy training fellowship from UCB and Eisai. She has also received travel funding from Eisai, UCB, and GlaxoSmithKline.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.Texto completo Resumen
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr;51(4):676-85. Resumen
Rosenow F, Wyllie E, Kotagal P, et al. Staring spells in children: descriptive features distinguishing epileptic and nonepileptic events. J Pediatr. 1998 Nov;133(5):660-3. Resumen
Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.Texto completo Resumen
Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141-55.Texto completo Resumen
Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia. 2005;46 Suppl 9:161-8. Resumen
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018 Jul 10;91(2):74-81.Texto completo Resumen
Nordli DR Jr. Idiopathic generalized epilepsies recognized by the International League Against Epilepsy. Epilepsia. 2005 Nov 18;46(suppl 9):48-56.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Daydreaming
- Attention deficit hyperactivity disorder (ADHD)
- Complex partial epilepsy of frontal or temporal lobe origin
Más DiferencialesGuías de práctica clínica
- Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication
- Epilepsies in children, young people and adults
Más Guías de práctica clínicaFolletos para el paciente
Absence seizures in children
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad